Ketamine for treatment-resistant depression : the first decade of progress / Sanjay J. Mathew , Carlos A. Zarate Jr., editors.
2016
RM315-334
Linked e-resources
Linked Resource
Online Access
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks
Details
Title
Ketamine for treatment-resistant depression : the first decade of progress / Sanjay J. Mathew , Carlos A. Zarate Jr., editors.
ISBN
9783319429250 (electronic book)
3319429256 (electronic book)
331942923X
9783319429236
3319429256 (electronic book)
331942923X
9783319429236
Publication Details
Switzerland : Adis, 2016.
Language
English
Description
1 online resource
Call Number
RM315-334
Dewey Decimal Classification
615.7/81
Summary
This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation ℓ́ℓketamine-likeℓ́ℓ fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamineℓ́ℓs psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamineℓ́ℓs rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamineℓ́ℓs rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.
Access Note
Access limited to authorized users.
Added Author
Mathew , Sanjay J.
Zarate, Carlos A. Jr.
Zarate, Carlos A. Jr.
Available in Other Form
Print version: 9783319429236
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
All Resources